Welcome to our dedicated page for Jazz Pharmaceuticals Plc news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals Plc stock.
Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) is a global biopharmaceutical leader developing life-changing therapies for complex conditions in oncology, neuroscience, and sleep medicine. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate milestones, regulatory developments, and clinical research advancements.
Our curated collection features official press releases, earnings reports, and analysis of strategic initiatives. Users can track key updates including FDA regulatory decisions, clinical trial results, and therapeutic portfolio expansions. The resource prioritizes accuracy and comprehensiveness, serving as a primary source for understanding Jazz's market position.
Content spans multiple categories essential for informed decision-making: product approvals, research collaborations, financial performance, and manufacturing updates. Each entry maintains strict editorial standards to ensure relevance to both clinical and investment communities.
Bookmark this page for streamlined access to Jazz Pharmaceuticals' latest developments. Check regularly for updates on innovative therapies addressing narcolepsy, epilepsy, and hematologic malignancies, supported by the company's established R&D expertise.
Jazz Pharmaceuticals (JAZZ) announced strong financial results for Q1 2022, reporting $813.7 million in total revenues, a 34% increase year-over-year. The company raised its full-year revenue guidance to $3.5 to $3.7 billion, citing momentum from recent product launches like Xywav for narcolepsy and idiopathic hypersomnia. The net income was $1.6 million ($0.03 per share), significantly lower than $121.8 million from a year earlier. Strategic divestitures and new product developments are set to enhance the company's focus and long-term value.
Jazz Pharmaceuticals has secured exclusive rights to develop and commercialize DSP-0187 in the U.S., Europe, and other regions through a licensing agreement with Sumitomo Pharma. The agreement includes a $50 million upfront payment and up to $1.09 billion in milestone payments. Jazz aims to expedite the development of DSP-0187, a novel oral orexin-2 receptor agonist for treating narcolepsy and other sleep disorders. This collaboration aligns with Jazz's commitment to innovation in sleep medicine, leveraging its expertise in delivering therapies that enhance patient care.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced its participation in the BofA Securities 2022 Global Healthcare Conference on May 10, 2022, at 12:40 p.m. PT / 3:40 p.m. ET in Las Vegas. An audio webcast will be available on the Investor section of their website, with a replay archived for 30 days. Jazz Pharmaceuticals is dedicated to developing innovative medicines in neuroscience and oncology, serving patients in nearly 75 countries. For more details, visit www.jazzpharmaceuticals.com.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will report its 2022 first quarter financial results on May 4, 2022, after U.S. market close. Management will host a live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The U.S. and international dial-in numbers for the conference call are provided. A replay will be available until May 11, 2022. Jazz Pharmaceuticals focuses on developing innovative medicines for serious diseases, maintaining a diverse portfolio of marketed medicines and product candidates in neuroscience and oncology.
Jazz Pharmaceuticals presented promising pre-clinical data for its investigational drug JZP815 at the AACR Annual Meeting. The pan-RAF kinase inhibitor showed effectiveness in inhibiting tumor growth in various RAS- and BRAF-mutated solid tumor models and enhanced activity when combined with other MAPK inhibitors. Jazz plans to submit an IND for JZP815 this year, targeting challenging cancers like colorectal and non-small cell lung cancer. The drug's unique mechanism minimizes paradoxical pathway activation, potentially addressing unmet medical needs.
Jazz Pharmaceuticals has entered a licensing agreement with Werewolf Therapeutics for WTX-613, an innovative immuno-oncology therapy. Jazz will pay $15 million upfront, with up to $1.26 billion in potential milestone payments. WTX-613 aims to enhance cancer treatment by minimizing systemic toxicity associated with conventional therapies. This program expands Jazz's oncology pipeline, with an IND application planned for submission in 2023. Both companies express optimism about the collaboration and the future potential of WTX-613 in treating various cancers.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is set to participate in key investor conferences in April 2022. The first event is the J.P. Morgan 11th Annual Napa Valley Biotech Forum on April 5, where management will engage in a fireside chat at 12:00 p.m. ET. The second event is the Needham Virtual Annual Healthcare Conference on April 11, featuring a panel on Future Treatment Trends in Epilepsy at 11:45 a.m. ET. Jazz is dedicated to developing innovative therapies in neuroscience and oncology, serving patients in nearly 75 countries.
Jazz Pharmaceuticals announces a definitive agreement to divest Sunosi (solriamfetol) to Axsome Therapeutics for an upfront payment of $53 million, along with royalty rights. Sunosi, indicated for excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea, will generate high single-digit royalties on U.S. net sales. This transaction aims to sharpen Jazz's focus on strategic growth in neuroscience and oncology, ensuring uninterrupted patient access to Sunosi during the transition. Completion is expected in Q2 2022, contingent on regulatory approvals.
Jazz Pharmaceuticals has begun construction on a new 60,000 sq. ft. manufacturing facility at Kent Science Park, investing $100 million (£75m) and creating over 100 skilled jobs. The facility, expected to open in 2024, will support the company's regulatory-approved cannabis-based medicines and future developments. This strategic investment underscores Jazz's commitment to the UK market and aims to enhance production capacity. Additionally, the facility will feature eco-friendly designs with solar panels and wildlife promotion measures.
Jazz Pharmaceuticals announced the enrollment of the first patient in a Phase 2 clinical trial, EMERGE-201, assessing the safety and efficacy of Zepzelca (lurbinectedin) for patients with advanced urothelial carcinoma, large cell neuroendocrine carcinoma of the lung, and homologous recombination deficient tumors. The trial will evaluate patient objective response rates as the primary endpoint. With approximately 20 sites in the U.S. participating, the trial aims to address unmet needs in treating these cancers that lack effective therapies beyond traditional chemotherapy.
FAQ
What is the current stock price of Jazz Pharmaceuticals Plc (JAZZ)?
What is the market cap of Jazz Pharmaceuticals Plc (JAZZ)?
